Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Withdrawn

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2008-09-25

Last Posted Date: 2012-01-11

Lead Sponsor: University of Kentucky

Registration Number: NCT00758693

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: dexamethasone
Drug: Bendamustine

First Posted Date: 2008-08-25

Last Posted Date: 2016-03-16

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 39

Registration Number: NCT00740415

Locations: 🇫🇷
CHU de Grenoble - Hopital Michallon, Grenoble, France

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: bendamustine hcl

First Posted Date: 2008-06-26

Last Posted Date: 2017-03-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00705250

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Bendamustine

First Posted Date: 2008-04-18

Last Posted Date: 2011-09-02

Lead Sponsor: German Breast Group

Target Recruit Count: 38

Registration Number: NCT00661739

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: VELCADE
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2008-03-14

Last Posted Date: 2012-01-13

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 73

Registration Number: NCT00636792

Locations: 🇺🇸
MidDakota Clinic - Cancer Treatment and Research Center, Bismarck, North Dakota, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma

First Posted Date: 2008-02-11

Last Posted Date: 2010-07-22

Lead Sponsor: SymBio Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT00612183

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: bortezomib
Drug: bendamustine
Drug: rituximab

First Posted Date: 2007-10-22

Last Posted Date: 2015-08-06

Lead Sponsor: University of Rochester

Target Recruit Count: 31

Registration Number: NCT00547534

Locations: 🇺🇸
Cornell Wiell Medical College, New York, New York, United States
🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of Rochester Medical Center (James P. Wilmot Cancer Center), Rochester, New York, United States